Scope and Claims Dissection of US Patent 9,206,187 (3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile), plus a US Patent Landscape View
US 9,206,187 is drafted as an oral, sustained-release method-of-treatment claim set built around one specific small-molecule scaffold (3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile] and its pharmaceutically acceptable salts), with an expansive disease genus and layered dependent claim limitations focused on (i) a particular stereoisomer, (ii) specific target indications, and (iii) oral unit dosage formulation features (tablet/capsule, enteric coating, excipients, and mg range).
The practical claim scope is broad at the independent claim level (drug + oral sustained release + treating/ameliorating/inhibiting a long list of diseases), but commercially narrower when you map it to real-world development constraints: to infringe, accused products typically must be oral and sustained-release and contain the claimed compound or a salt (or fall into a doctrine-of-equivalents position for a salt/form), and the dispute often turns on whether the accused formulation is “suitable for… providing sustained release” and whether the dosage form and excipients are within the dependent-claim fences.
What does US 9,206,187 claim protect: method-of-treatment using an oral sustained-release of a specific nitrile scaffold?
Direct answer (claim 1): The patent covers a method of treating a disease by administering an oral sustained-release pharmaceutical composition containing 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (or salt) + a pharmaceutically acceptable carrier, where treatment is ameliorating or inhibiting the disease.
Claim 1: element-by-element scope map (infringement-relevant)
A. “Method of treating a disease selected from [very broad list]”
The independent claim uses a Markush-style disease selection. The list includes cachexia, PV, ET, MMM, CML, CMML, HES, SMCD, acute myelogenous leukemia, multiple myeloma, pancreatic cancer, leukemia, lymphoma, breast cancer, acute lymphoblastic leukemia, and Castleman’s disease.
- Scope consequence: A product aimed at any listed indication can fall within claim 1 without needing claim construction on a mechanism term. The claim does not require a biomarker or pathway-specific mechanism, only a therapeutic effect defined as “ameliorating or inhibiting.”
B. “Administering… a pharmaceutical composition comprising [specified compound] or a pharmaceutically acceptable salt”
This is a compound-limited method claim. It does not read on close analogs unless they are captured by “pharmaceutically acceptable salt thereof” around the specific structure.
- Scope consequence: If an accused drug uses a materially different core structure, the claim typically fails at this element.
C. “Oral administration”
This limits the claim to oral dosing forms.
- Scope consequence: Parenteral formulations of the same compound generally do not satisfy this limitation for literal infringement.
D. “Sustained release”
“Suitable for… providing sustained release” is a formulation-performance label in the claim text.
- Scope consequence: This is often the infringement flashpoint. Litigation will typically focus on release profile, dissolution method, pharmacokinetic behavior, and formulation design. A product marketed as extended-release or having prolonged absorption windows is an obvious risk area, even if not branded “SR.”
E. “Pharmaceutically acceptable carrier”
This is classic open-ended formulation language.
- Scope consequence: Carriers are not limiting beyond being pharmaceutically acceptable.
F. “Treating refers to ameliorating or inhibiting the disease”
No degree of effect is stated (no percent response, no time-to-event metric, no specific clinical endpoint).
- Scope consequence: “Inhibiting” and “ameliorating” can be broadly argued; claim validity and enforcement often hinge on prior art and whether the specification supports the broad indication genus.
How does the stereoisomer limitation narrow US 9,206,187 claim scope?
Direct answer (claim 2): Claim 2 narrows claim 1 to the (3R) enantiomer of the compound (or a pharmaceutically acceptable salt of that enantiomer).
Practical scope effect of (3R) limitation
- If the marketed API is racemic, and the claim construction requires the (3R) species itself, infringement becomes fact-driven: whether the racemate includes the (3R) enantiomer in a sufficient sense to meet “the compound is (3R)…”
- If the accused API is explicitly enantiopure (3R), the risk increases.
- If the accused API is the (3S) enantiomer or different stereochemical arrangement, the claim likely does not read.
What indications are covered by US 9,206,187 and how does dependent claims change enforcement posture?
Direct answer: The independent claim already lists many diseases; dependent claims (3–17) repeat them as “wherein the disease is X,” tying the same oral sustained-release (3R) compound limitation to each named indication.
Dependent claims by indication (claims 3–17)
- Claim 3: PV
- Claim 4: ET
- Claim 5: MMM
- Claim 6: CML
- Claim 7: CMML
- Claim 8: acute myelogenous leukemia
- Claim 9: multiple myeloma
- Claim 10: pancreatic cancer
- Claim 11: leukemia
- Claim 12: lymphoma
- Claim 13: breast cancer
- Claim 14: acute lymphoblastic leukemia
- Claim 15–16: cachexia (with cachexia resulting from or associated with cancer)
- Claim 17: Castleman’s disease
Enforcement consequence
- Even though claim 1 contains the list, the dependent claim structure gives patentees multiple “clean” claim paths to match an accused label indication.
- In litigation, proving that the product’s intended use/labeling supports a specific disease can strengthen infringement, even if claim 1 already covers it.
What formulation and dosage-form limitations are in US 9,206,187 claims 18–26?
Direct answer: Claims 18–26 narrow to unit dosage forms (tablet or capsule) and further to optional enteric coating and specific dose range and excipients.
Claim 18: unit dosage form
- “composition is a unit dosage form” is a meaningful limitation: multi-dose bottles, sachets, or liquid dosing regimens are more likely to fall outside depending on product presentation.
Claim 19–21: tablet/capsule + enteric coating
- Claim 19: unit dosage form is a tablet
- Claim 20: unit dosage form is a capsule
- Claim 21: unit dosage form further comprises an enteric coating
Risk note: Enteric coating can be a common design choice for oral absorption and GI tolerability. If accused products are enteric-coated extended-release forms, the risk aligns with both “sustained release” and “enteric coating” limitations.
Claim 22: mg range
- “from about 5 to about 1000 mg” of compound or salt
This is a broad range, but it still can matter if accused dose strengths fall outside it.
Claims 23–26: excipient recitations
- Claim 23: further comprises one or more excipients selected from a long list
- Claim 24: microcrystalline cellulose
- Claim 25: lactose
- Claim 26: microcrystalline cellulose and lactose
How excipient-dependent claims change infringement
- If a product does not use the recited excipients, those dependent claims can be avoided.
- But because claim 23 is written as “one or more excipients selected from” a broad set, many conventional oral solids will satisfy claim 23. The pairwise specificity in claims 24–26 is where design-around can be attempted: remove lactose or avoid microcrystalline cellulose. Whether that is practical depends on manufacturability and regulatory constraints.
How strong is the patent’s claim breadth for US infringement: “oral sustained release + specific compound + broad disease genus”
Direct answer: As a method-of-treatment patent with a compound anchor, US 9,206,187 has high coverage breadth at claim 1 and additional formulation-specific fence posts in dependent claims.
Breadth boosters (pro-patentee)
- Disease genus is wide. It covers both hematologic malignancies and solid tumors and even supportive syndromes (cachexia).
- Mechanism is not required. “Ameliorating or inhibiting” is functional.
- Formulation language is permissive via “suitable for sustained release” and a broad “carrier.”
- Dependent claims add multiple “litigation hooks”: dosage form type, enteric coating, dosage strength range, and common excipient recitations.
Breadth risks (attack surfaces)
- Sustained-release construction is fact-intensive and may require technical evidence. A product can potentially be argued not to be “suitable for… providing sustained release” depending on release profile and intended absorption.
- Stereoisomer specificity in claim 2 can be an avenue for avoiding dependent coverage if accused API is not (3R).
- Dependent claims provide partial escape routes if an accused product avoids the specific dosage form or excipient combination, though independent claim 1 may still be in play.
What does the claim set imply about the patent’s invention category (method-of-treatment vs formulation vs use)?
This patent is best categorized as a compound-linked, oral sustained-release use patent:
- It is not drafted as a pure formulation claim (no explicit polymer matrix, coating thickness, or specific dissolution kinetics).
- It is not drafted as a surgical or administration sequence method.
- It is drafted as therapeutic use with administration form descriptors: oral + sustained release.
For businesses, that means:
- Generic or competitor challenge is typically focused on (i) design-around to non-sustained-release form, (ii) stereochemistry choice, and/or (iii) indication or intended-use strategy tied to regulatory labeling.
How many separate legal “claim lanes” exist in US 9,206,187 for infringement arguments?
Direct answer: At least two core lanes and multiple sub-lanes:
-
Core lane: claim 1
Oral sustained-release composition + compound (or salt) + treating disease.
-
Core lane: claim 2
Same as claim 1 but limited to (3R) enantiomer.
-
Indication sub-lanes: claims 3–17
Map directly to labeled or prosecuted indications.
-
Formulation sub-lanes: claims 18–26
Unit dosage form (tablet/capsule), possible enteric coating, dose range, and excipient inclusion.
This structure lets an enforcement strategy plead alternative infringement theories even if one depends on formulation facts.
US patent landscape: what other US patents typically surround an oral sustained-release use claim for a single scaffold?
A method-of-treatment claim like US 9,206,187 usually sits within a dense family architecture that includes, at minimum, some combination of:
- Synthesis/chemical process patents for the compound (and stereochemical variants)
- Compound structure patents (core scaffold claims)
- Salt form patents (specific salts and polymorphs)
- Formulation patents (extended-release matrix/coating details)
- Use patents (mechanistic or indication-specific claims, sometimes biomarker-driven)
- Combination therapy patents (same compound plus partner drugs)
However, without the specific bibliographic data for US 9,206,187 (assignee, priority date, family members, application publication, and the related “Related US” patent list), a complete landscape table of co-pending or expired family patents cannot be generated from the provided claim text alone.
Accordingly, no numbered claim-to-patent landscape mapping is included here.
What generic entry risks exist under US 9,206,187 for oral sustained-release (3R) products?
Direct answer: The principal generic entry risk is not “generic vs branded API” in the abstract. It is whether an ANDA/505(b)(2) product is an oral sustained-release version that contains the claimed compound (or salt) and, if targeting covered indications, is used for that treatment.
Risk profiles by likely design-around lever
- Switch to immediate-release: could attempt to avoid “suitable for… sustained release,” but FDA product performance characterization and labeling may undercut this.
- Switch stereochemistry: if the branded API uses (3R), a generic could try to market another stereoisomer. Whether that is viable depends on pharmacology and regulatory acceptance.
- Salt selection: the claim covers “pharmaceutically acceptable salt thereof.” A generic must pick a salt that is not a “salt thereof” or argue it is not pharmaceutically acceptable or not within claim scope.
- Formulation excipients and dose form: claims 24–26 can be potentially avoided by removing lactose or microcrystalline cellulose, but claim 1 and 2 remain.
What patent expiration and regulatory exclusivity triggers govern when the claims can be enforced or expire?
No expiration calculation is possible from the provided material because enforcement timing depends on:
- filing date vs priority date,
- patent term adjustments,
- patent term extensions,
- whether there is relevant exclusivity under Hatch-Waxman (Orange Book) or biologics frameworks (not applicable if this is a small molecule method patent),
- and the presence of continuation/divisional filings.
As a result, no exclusivity timeline is included here.
Key Takeaways
- US 9,206,187 claim 1 is a broad method-of-treatment claim: oral + sustained release + specified compound (or salt) + disease genus with functional therapeutic language (“ameliorating or inhibiting”).
- Claim 2 narrows compound coverage to the (3R) enantiomer, creating a stereochemistry-driven design-around lane for some competitors.
- Dependent claims 3–17 align the method claims to specific hematologic and solid tumor indications, improving enforcement fit to labeled uses.
- Dependent claims 18–26 add formulation fences: unit dosage form, tablet/capsule, optional enteric coating, a 5–1000 mg strength range, and specific excipient recitations including lactose and microcrystalline cellulose.
- For infringement risk, the most consequential factual issues are: (i) whether the product is “oral” and “suitable for sustained release,” (ii) whether the API is the claimed compound/salt and in the (3R) form for dependent coverage, and (iii) the product’s formulation descriptors for the dependent claims.
FAQs
1) What does “suitable for providing sustained release” require for infringement of US 9,206,187?
It is a formulation-performance limitation. Practically, it turns on release kinetics and whether the accused product is designed and characterized to release drug over an extended period.
2) Does US 9,206,187 cover immediate-release versions of the compound?
Claim 1 requires “oral administration” and “providing sustained release,” so immediate-release versions are generally outside claim 1 if they are not suitable for sustained release.
3) How does the (3R) limitation affect enforcement against a racemate?
Claim 2 recites the compound “is (3R).” Whether a racemate satisfies that depends on claim construction and the accused product’s enantiomeric composition and how “is” is construed for enantiomer-containing mixtures.
4) Can competitors avoid claims 24–26 by changing excipients?
Yes in principle. Claims 24–26 specifically recite microcrystalline cellulose and lactose combinations; removing one or both can avoid those dependent claims, though independent claims may still apply.
5) Does the patent require a specific mechanism of action or biomarker?
No. The claims define treatment functionally as “ameliorating or inhibiting the disease,” without requiring mechanistic proof terms in the claim language.
References (APA)
- United States Patent 9,206,187 (claims provided in prompt).
